James Kuo

James S.
Kuo founded Windtree Therapeutics, Inc. in 1992, where he worked as President & Chief Executive Officer, BioMicro Systems, Inc. in 2003, where he worked as Chairman & Chief Executive Officer from 2003 to 2006, and Tryp Therapeutics, Inc. in 2019, where he worked as Chief Executive Officer & Director from 2019 to 2021.
Dr. Kuo also founded Monarch Labs, Inc., where he is working as Chairman & Manager.
Dr. Kuo also currently works at ApoLife, Inc., as Chairman & Chief Executive Officer from 2012, Return Health, Inc., as Chief Executive Officer, MSK Pharma LLC, as Non-Executive Chairman, Athena Bioventures, Inc, as Managing Director from 2007, Silo Pharma, Inc., as Vice President-Research & Development from 2022, and Pharnext SA, as Member-Supervisory Board from 2023.
Dr. Kuo also formerly worked at FIT Biotech Oy, as Chief Executive Officer & IR Contact from 2016 to 2018, Cysteine Pharma, Inc., as Chairman & Chief Executive Officer from 2006 to 2007, ONCOtracker, Inc., as Chief Executive Officer from 2018 to 2019, KMRB Acquisition Corp.
II, as Chairman & Chief Executive Officer, Theriva Biologics, Inc., as President, Chief Executive Officer & Director, Soligenix, Inc., as Non-Executive Chairman from 2004 to 2009, MindWalk Holdings Corp., as Chairman from 2016 to 2023, Pfizer Inc., as Associate Director-Corporate Licensing from 1995 to 1997, HealthCare Ventures LLC, as Managing Director-Venture Analysis, Cordex Pharma, Inc., as Director from 2007 to 2010, and Myriad Genetics, Inc., as Vice President-Business Development from 1998 to 2000.
Dr. Kuo received his undergraduate degree from Haverford College, Masters Business Admin degree from The Wharton School of the University of Pennsylvania, and doctorate degree from the University of Pennsylvania Medical Center.